Demonstration of an anti-oxidative stress mechanism of quetiapine: Implications for the treatment of Alzheimer's disease

FEBS Journal

Volumn 275, Issue 14, 2008, Pages 3718-3728

  Xu, Haiyun ^a,b   Wang, Haitao ^c   Zhuang, Lixia ^d   Yan, Bin ^c   Yu, Yingxin ^c   Wei, Zelan ^c   Zhang, Yanbo ^c   Dyck, Lillian E ^c   Richardson, Steven J ^c   He, Jue ^c   Li, Xiaokun ^b   Kong, Jiming ^e   Li, Xin Min ^b,c,e  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d BEIJING INSTITUTE OF TECHNOLOGY   (China)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Alzheimer's disease; Anti oxidant; Beta peptide; Oxidative stress; Quetiapine

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; QUETIAPINE; REACTIVE OXYGEN METABOLITE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (25 35); AMYLOID BETA-PROTEIN (25-35); ANTIOXIDANT; DIBENZOTHIAZEPINE DERIVATIVE; HYDROXYL RADICAL; NEUROLEPTIC AGENT; PEPTIDE FRAGMENT; SCAVENGER;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ELECTRON SPIN RESONANCE; MASS SPECTROMETER; NONHUMAN; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; SPIN TRAPPING; ANIMAL; CELL STRAIN; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; ULTRASTRUCTURE;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FREE RADICAL SCAVENGERS; HYDROXYL RADICAL; OXIDATIVE STRESS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; REACTIVE OXYGEN SPECIES;

EID: 50549100242     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06519.x     Document Type: Article

References (54)

1. Cheer SM & Wagstaff AJ (2004) Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 18, 173-199.
2. Purdon SE, Malla A, Labelle A & Lit W (2001) Neuro-psychological changes in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psy-chiat Neurosci 26, 137-149.
3. Kivircik Akdede BB, Alptekin K, Kitis A, Arkar H & Akvardar Y (2005) Effects of quetiapine on cognitive functions in schizophrenia. Prog Neuro-psychoph 29, 233-238.
4. Small JG, Hirsch SR, Arvanitis LA, Miller RG & Link CG (1997) Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiat 54, 549-557.
5. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H & Yamawaki S (2004) Quetia-pine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 49, 201-204.
6. Onor ML, Saina M & Aguglia E (2007) Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. Am J Alzheimers Dis Other Demen 21, 448-453.
7. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M & Williams-Hughes C (2006) Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiat 14, 767-776.
8. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, Jou HC & Yeung PP (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 19, 29-35.
9. Bai O, Wei Z, Lu W, Bowen R, Keegan D & Li XM (2002) Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 69, 278-283.
10. Qing H, Xu H, Wei Z, Gibson K & Li XM (2003) The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 17, 1563-1570.
11. Wei Z, Mousseau DD, Richardson JS, Dyck LE & Li XM (2003) Atypical antipsychotics attenuate neurotox-icity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 74, 942-947.
12. Wang H, Xu H, Dyck LE & Li XM (2005) Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 81, 572-580.
13. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X et al. (2007) Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging, doi: 10.1016/j.neurobio- laging.2007.11.001.
14. Lorenzo A & Yankner BA (1994) b-Amyloid neurotox-icity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91, 12243-12247.
15. Varadarajan S, Kanski J, Aksenova M, Lauderback C & Butterfield DA (2001) Different mechanisms of oxi-dative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J Am Chem Soc 123, 5625-5631.
16. Behl C (1997) Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res 290, 471- 480.
17. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA & Butterfield DA (1994) A model for b-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci USA 91, 3270-3274.
18. Hensley K, Aksenova M, Carney JM, Harris M & But-terfield DA (1995) Amyloid β-peptide spin trapping I: peptide enzyme toxicity is related to free radical spin trap reactivity. Neuroreport 6, 493-496.
19. Tabner BJ, Turnbull S, King JE, Benson FE, El-Agnaf OM & Allsop D (2006) A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein. Free Radical Res 40, 731-739.
20. 25-35 region to aggregation and neurotoxicity. J Neuro-chem 64, 253-265.
21. Zhou Y, Gopalakrishnan V & Richardson JS (1996) Actions of neurotoxic β-amyloid on calcium homeosta-sis and viability of PC12 cells are blocked by antioxi-dants but not by calcium channel antagonists. J Neurochem 67, 1419-1425.
22. Behl C, Davis JB, Lesley R & Schubert D (1994) Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77, 817-827.
23. Richardson JS, Zhou Y & Kumar U (1996) Free radicals in the neurotoxic actions of beta-amyloid. Ann NY Acad Sci 777, 362-367.
24. Mohmmad Abdul H, Wenk GL, Gramling M, Hauss-Wegrzyniak B & Butterfield DA (2004) APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. Neurosci Lett 368, 148-150.
25. Behl C (1999) Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 57, 301-323.
26. Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77, 1081-1132.
27. Boraldi F, Annovi G, Paolinelli-Devincenzi C, Tiozzo R & Quaglino D (2008) The effects of serum withdrawal on the protein profile of quiescent human dermal fibroblasts in primary cell culture. Proteomics 8, 66-82.
28. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC & Cha BS (2007) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253, 53-60.
29. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D et al. (1996) Increased amyloid-β42(43) in brains of mice expressing mutant presenilinl. Nature 383, 710- 713.
30. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F & Cole G (1996) Correlative memory deficits, abeta elevation, and amyloid plaque in transgenic mice. Science 274, 99-102.
31. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, Hashimoto Y, Maruyama K, Tanuma S, Kiso Y et al. (2006) The novel beta-secretase inhibitor KMI- 429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neu-rochem 96, 533-540.
32. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H et al. (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101, 3632-3637.
33. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D et al. (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9, 3-4.
34. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X & Song W (2005) Oxidative stress potentiates BACEI gene expression and a-beta generation. J Neural Transm 112, 455-469.
35. Rao AV & Balachandran B (2002) Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5, 291-309.
36. Tabner BJ, Turnbull S, El-Agnaf OM & Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radical Biol Med 32, 1076-1083.
37. Yao JK, Reddy RD & van Kammen DP (2001) Oxida-tive damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15, 287-310.
38. Akyol O, Herken H, Uz E, Fadillioǧlu E, Unal S, Söǧüt S, Ozyurt H & Savaş HA (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuro-psychoph 26, 995-1005.
39. Karry R, Klein E & Shachar DB (2004) Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiat 55, 676-684.
40. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS et al. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiat 9, 684- 697.
41. Davis PC, Wong J & Gefvert O (1999) Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal 20, 271-282.
42. Cadet JL & Lohr JB (1989) Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 570, 176-185.
43. Post A, Holsboer F & Behl C (1998) Induction of NF-kappaB activity during haloperidol-induced oxida-tive toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 18, 8236-8246.
44. Pai BN, Janakiramaiah N, Gangadhar BN & Ravindr-anath V (1994) Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiat 36, 489-491.
45. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Rüther E, Emrich HM, Schneider U & Bleich S (2005) Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuro-psych Clin N 17, 227-231.
46. Bressan RA, Jones HM & Pilowsky LS (2004) Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J Psychopharmacol 18, 124-127.
47. Fountoulakis KN, Panagiotidis P, Siamouli M, Kan-tartzis S, Mavridis T, Iacovides A & Kaprinis G (2006) Amisulpride-induced tardive dyskinesia. Schizophr Res 88, 232-234.
48. Vesely C, Kufferle B, Brucke T & Kasper S (2000) Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 15, 57-60.
49. Scharre DW & Chang SI (2002) Cognitive and behavioral effects of quetiapine in Alzheimer's disease patients. Alzheimer Dis Assoc Disord 16, 128-130.
50. Onor ML, Saina M & Aguglia E (2006) Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. Am J Alzheimers Dis Other Demen 21, 448-453.
51. Daniel DG (2000) Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiat 61(Suppl. 14), 49-52.
52. LeVine H III (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2, 404- 410.
53. Skribanek Z, Balaspiri L & Mak M (2001) Interaction between synthetic amyloid-beta;-peptide(1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom 36, 1226-1229.
54. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440-3450.